Press Releases April 5, 2026 08:00 PM

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals Announces Participation in Key April 2026 Investor Conferences

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
PHAT

Phathom Pharmaceuticals, a biopharmaceutical company specializing in gastrointestinal disease treatments, will have its management team participate in the Raymond James 2026 Biotech Innovation Symposium and the 25th Annual Needham Virtual Healthcare Conference in April 2026, including a fireside chat and one-on-one meetings. The company markets VOQUEZNA® products for GERD and H. pylori infections.

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
PHAT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Phathom will engage investors through key biotech and healthcare conferences in April 2026.
  • Management will conduct one-on-one meetings and participate in a fireside chat, enhancing investor communications.
  • The company markets VOQUEZNA® and related combination therapies for gastrointestinal conditions such as GERD and H. pylori infections.
  • Sectors impacted include biotechnology, pharmaceuticals, and healthcare markets.

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April:

Raymond James 2026 Biotech Innovation Symposium in New York, NY
Date: Tuesday, April 14, 2026
Management to participate in one-on-one meetings throughout the conference

25th Annual Needham Virtual Healthcare Conference
Date: Wednesday, April 15, 2026
Fireside Chat: 1:30 pm EDT
Management to participate in one-on-one meetings throughout the conference

To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.


Risks

  • Investor perception and conference outcomes may impact stock volatility and valuation.
  • Market competition in gastrointestinal therapeutics may affect commercial performance.
  • Regulatory and reimbursement environments remain uncertainties affecting future growth prospects.

More from Press Releases

V Gallant’s Fintech Partner Credilab Secures Full Online Lending Approval in Malaysia, Advancing Revenue-Share AI Lending Platform Jun 8, 2026 Nexera Technologies: Subsidiary Fort Technology Commences Trading on Nasdaq Under Ticker “FRTT” Today Jun 8, 2026 Foresight Secures $17.5 Million Strategic Investment from VisionWave at a $34 Million Valuation Post Investment to Advance AI Perception Capabilities for Defense and Security Jun 8, 2026 AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer Jun 8, 2026 Consolidated Water Appoints Water Industry Veteran Sachin Chawla as Senior Vice President, Strategy and Growth Jun 8, 2026